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Proteins that regulate the coagulation cascade, including thrombin, are elevated in the brains of Alzheimer’s
disease (AD) patients. While studies using amyloid-based AD transgenic mouse models have implicated thrombin
as a protein of interest, the role of thrombin in tau-based animal models has not been explored. The current study
aims to determine how inhibiting thrombin could alter oxidative stress, inflammation, and AD-related proteins in
a tau-based mouse model, the Tg4510. Aged Tg4510 mice were treated with the direct thrombin inhibitor
dabigatran or vehicle for 7 days, brains collected, and western blot and data-independent proteomics using mass
spectrometry with SWATH-MS acquisition performed to evaluate proteins related to oxidative stress, intracel
lular signaling, inflammation, and AD pathology. Dabigatran reduced iNOS, NOX4, and phosphorylation of tau
(S396, S416). Additionally, dabigatran treatment increased expression of several signaling proteins related to cell
survival and synaptic function. Increasing evidence supports a chronic procoagulant state in AD, highlighting a
possible pathogenic role for thrombin. Our data demonstrate that inhibiting thrombin produces alterations in the
expression of proteins involved in oxidative stress, inflammation, and AD-related pathology, suggesting that
thrombin-mediated signaling affects multiple AD-related pathways providing a potential future therapeutic
target.

1. Introduction
Cardiovascular disease and cardiovascular risk factors (CVRFs) are
strongly associated with an increased risk of developing dementia,
particularly Alzheimer’s disease (AD) [1]. While the connection be
tween CVRFs and AD is well-documented, mechanisms whereby these
risk factors confer elevated AD risk have not been delineated. It is likely
that one or more pathological mediators involved in the progression of
cardiovascular diseases contributes to AD pathology. The multifunc
tional protease thrombin is implicated in the development of athero
sclerosis and diabetes, and more recently suggested as a novel mediator
in AD [2,3].

Thrombin is a pleiotropic enzyme that triggers a large and diverse
number of cellular events, largely through activation of proteaseactivated receptors (PARs) [4]. Recent evidence indicates that coagu
lation proteins, including thrombin, also mediate oxidative stress and
neuroinflammation, invariant features of neurodegenerative diseases
[5]. To that end, thrombin increases NADPH-dependent superoxide
anion and hydrogen peroxide production, and injures neurons via
microglial release of nitric oxide (NO) [6,7]. In a primarily
amyloid-based AD mouse model (3xTgAD), we have previously shown
that administration of the thrombin inhibitor dabigatran significantly
decreases expression of reactive oxygen species (ROS) and inflammatory
proteins in these mice [8].
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There is evidence that thrombin is relevant for AD pathology. Spe
cifically, thrombin is expressed in AD-derived, but not control brain
microvessels [9], and the thrombin inhibitor protease nexin-1 is reduced
in the perivascular space, suggesting that vascular-derived thrombin is
increased [10]. Levels of both thrombin and the thrombin receptor
PAR-1 are elevated in AD [11]. Thrombin accumulation has also been
identified in neurofibrillary tangles, and signaling through the thrombin
receptor induces tau aggregation and related hippocampal degeneration
[12]. Thrombin’s role as a pathological mediator in a tau-based AD
model has not yet been explored. Currently, several tauopathy animal
models are being used to study AD, including Tg4510, which over
expresses human tau with a P301L mutation at 13:1 versus murine tau
[13]. These mice exhibit profound tau pathology and neuronal loss in
the hippocampus and cortex, as well as cognitive deficits and metabolic
changes that progress with age [14]. Tg4510 mice also display blood
vessel abnormalities accompanied by alterations in oxidative and in
flammatory markers [15].
Data linking thrombin to oxidative and inflammatory stress as well
as tau-related pathology suggest that thrombin could be a target for
therapeutic intervention in AD. The objective of the current study is to
investigate the potential therapeutic benefits of inhibiting thrombin in a
tau-based animal model of AD. In this pilot study, we explore the effects
of short-term treatment with direct thrombin inhibitor, dabigatran
etexilate, in aged Tg4510 mice. We hypothesize that inhibiting thrombin
will reduce oxidative stress and inflammation-related indicators corre
sponding to an overall reduction in AD-related pathology in the brain.

2.3. Pressure cycling technology-based protein digestion
Whole brain homogenates were digested using pressure cycling
technology (PCT) for LC-MS/MS SWATH acquisition following the
previously published method with slight modifications [16]. 500 μg of
protein sample was spiked with 2 ng of BSA and incubated with
dithiothreitol (100 mM) at 90 ◦ C for 15 min, with shaking. Iodoaceta
mide (200 mM) was added and samples were incubated at room tem
perature in the dark for 30 min. Protein was then precipitated using
ice-cold chloroform, methanol, and water (1:2:1) followed by centrifu
gation at 13,400 xG for 5 min at 10 ◦ C. The protein pellet was rinsed
with methanol and resuspended in 3% w/v sodium deoxycholate (DOC)
in 50 mM ammonium bicarbonate. Samples were placed in MicroTubes
(Pressure BioSciences Inc, South Easton, MA) with trypsin at a 1:20 ratio
of trypsin:protein. Digestion was performed at 55 ◦ C for 75 cycles (50 s
at 35kpsi, 10 s at ambient pressure) in a Barocycler NEP2320-45k
(Pressure BioSciences Inc). A second digestion was performed by add
ing fresh trypsin at the same ratio for an additional 60 cycles. Digestion
was stopped and DOC was precipitated by the addition of formic acid in
acetonitrile at a final percentage of 0.5%. Samples were centrifuged and
supernatant was collected for analysis.
2.4. Data independent proteomics using mass spectrometry with SWATHMS acquisition
Mass spectrometry was performed as previously described with
minor modifications [16,17]. Samples were analyzed on a SCIEX Tri
pleTOF® 5600 mass spectrometer using a DuoSpray™ ion source
(SCIEX, Framingham, MA) coupled to an Acquity HClass UHPLC system
(Waters Corp., Milford, MA). Separation was achieved on an Acquity
UPLC Peptide BEH C18 column (2.1 x 150 mm, 300 Å, 1.7 μm) with an
Acquity VanGuard pre-column (2.1 x 5 mm, 300 Å, 1.7 μm). The column
temperature was set to 50 ◦ C and the autosampler was set to 10 ◦ C.
Mobile phase A consisted of 99.9% acetonitrile and 0.1% formic acid.
Mobile phase B consisted of 99.9% water and 0.1% formic acid. A linear
gradient was used with a flow rate of 100 μL/min for 90 min, as pre
viously published [17]. A mixture of trypsin-digested β-galactosidase
peptides were used between every 8 samples to calibrate masses and
monitor the TOF detector.
Positive ionization mode was used for data dependent acquisition.
The mass spectrometer parameters are as follows: gas 1, gas 2, curtain
gas, temperature and ion spray voltage floating were 55 psi, 60 psi, 25
psi, 450 ◦ C, 5500 V, Respectively. Declustering potential was 10, colli
sion energy 10 and collision energy spread 15. For data acquisition, a
maximum of 50 candidate ions were monitored for each survey scan. All
ions had a charge state from 2 to 4. A range of m/z 300–1250 was used
for exclusion criteria and all ions that had an intensity greater than 25
cps were chosen for MS/MS analysis. The temperature was set at 450 ◦ C
and the total cycle time was 3.5 s with a mass tolerance of 50 mDa
during the first 0.75 s survey scan.
For SWATH analysis, all parameters were the same as above except
for the following: Seventy SWATH windows per cycle were collected
over m/z 400–1100 with each window size being m/z 10 and TOF
masses were collected from m/z 300 to 1500.

2. Materials and methods
2.1. Animals and treatment
Female transgenic Tg4510 AD mice (PF/CamKII-tTA Tg 129 x tetOMAPT(P301L) Tg (TG2510 TG/TG)) overexpressing human mutant tau
(P301L) and background matched controls (PF/CamKII-tTA Tg 129 x
tetO-MAPT(P301L) Tg-3 (TG2510 WT/WT)) were a kind gift from
MindImmune Therapeutics, Inc. originally obtained from Charles River
(Wilmington, MA). Mice were maintained on normal chow (ENVIGO
2020X, Huntingdon, UK) with water available ad libitum. At 15 months
of age, mice were treated via oral gavage with vehicle (2.5% DMSO,
2.5% koliphor EL, 90% diH2O) or dabigatran etexilate (100 mg/kg in
uniform suspension, Cayman Pharm, Ann Arbor, MI) daily for 7 days
(n≥4), and then euthanized. All animal procedures were performed in
accordance with NIH “Guide for the Care and Use of Laboratory Ani
mals” and University of Rhode Island Institutional Animal Care and Use
Committee (IACUC) guidelines.
2.2. Western blot
Whole brains minus the cerebellum were homogenized by sonication
(Branson SX150 Sonifier ®, Branson Ultrasonics, Danbury, CT) in
phosphate buffered saline (PBS) with protease inhibitors. Samples were
resolved in 4–20% poly-acrylamide gel and transferred to nitrocellulose
membrane. Membranes were blocked using antibody-specific concen
tration of Bovine Serum Albumin (BSA) or Milk in Tris-buffered saline +
Tween (TBS-T). Primary antibodies for this study include NOX4 (Sigma,
MA; 1:1000), iNOS (Abcam, MA; 1:250), and β-Actin (Santa Cruz, CA;
1:10,000). Tau and p-tau species were detected using phosphor-tau
family antibody sampler kit (Cell Signaling, MA; 1:500). Bound anti
body was detected with infrared secondary antibodies (Li-COR Bio
sciences, Lincoln, NE). Membranes were imaged using LiCor Odyssey
(LI-COR Biosciences, Lincoln, NE), and quantification was done in
ImageJ. Values for each protein were normalized to β-actin loading
control on the same blot.

2.5. Mass spectrometry data analysis
LC-MS/MS SWATH data was used to generate spectral libraries
through ProteinPilot (SCIEX, Framingham, MA). FASTA files for pro
teins of interest were downloaded from UniProt [18] and imported into
Skyline (MacCoss Lab, University of Washington). In Skyline, at least 3
transitions were selected per peptide, and at least 3 peptides per protein
were chosen. Once data was analyzed, the MPPreport (MacCoss Lab,
University of Washington) was generated and exported to Excel. In
Excel, transitions were averaged, and the sum of each peptide was
calculated to yield the total area under the curve representative of each
2
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protein. These were then standardized to internal standard, BSA.

was significantly (p < 0.01) elevated in Tg4510 mice compared to wild
type, and treatment of Tg4510 mice with dabigatran significantly (p <
0.05) reduced expression by 17.4% (Fig. 1B). Dabigatran treatment also
significantly modified the expression of NOX4 across groups (F = 6.305,
p < 0.05). Dabigatran treatment significantly (p < 0.01) reduced NOX4
expression by 24.7% compared to untreated Tg4510 mice (Fig. 1C).
Together, these findings suggest that dabigatran reduces oxidative stress
through reduction in enzyme expression.
In order to investigate the effect of dabigatran treatment on taurelated pathology, total tau and phosphorylated forms of tau S396 and
S416 were evaluated by western blot (Fig. 2). The expression of total tau
(F = 9.942, p < 0.01), S396 (F = 26.78, p < 0.001), and S416 (F = 11.67,
p < 0.0015) was significantly different across groups. Tg4510 mice
expressed 75.9% more total tau than wild type mice (p < 0.001).
Expression of both phosphorylated tau species S396 and S416 was
significantly (p < 0.001) elevated in Tg4510 mice compared to levels in
wild type mice. Treatment of Tg4510 mice with dabigatran significantly
(p < 0.05) lowered levels of both S396 (Fig. 2B) and S416 (Fig. 2C).
Furthermore, dabigatran treatment significantly (p < 0.05) reduced the
ratio of phosphorylated tau to total tau for both S396 and S416
(Table 1). S396 phosphorylation is found early in the disease course of
AD [26] and is related to destabilization of microtubules [27]. Phos
phorylation at S416 is largely found within the neuronal soma and has
been associated with the promotion of AD-related cell death [28].
Together, our findings indicate that dabigatran etexilate treatment may
reduce AD-related tau dysfunction through reduced phosphorylation.
LC-MS/MS SWATH analysis of all three treatment groups was un
dertaken based on proteins relevant for AD-related pathological pro
cesses as well as thrombin/dabigatran-related mechanisms including
proteins involved in the coagulation cascade, cell signaling, inflamma
tion, and AD. Protein sequences were obtained from the UniProt data
base and results from LC-MS/MS with SWATH acquisition were
analyzed in Skyline, an open source software for targeted proteomics
(Table 2). Significant differences in protein expression between wild
type and Tg4510 mice were identified and visualized with a volcano plot
(Fig. 3A). Further LC-MS/MS SWATH analysis was conducted to deter
mine differences in protein expression as a result of dabigatran

2.6. Statistical analysis
Data from each experiment are expressed as mean ± standard error
(SEM), unless otherwise indicated. All tests were performed in GraphPad
Prism (version 8.0). For Western blot, data were analyzed for signifi
cance using one-way analysis of variance (ANOVA) and multiple com
parisons carried out using the post-hoc Bonferroni test. For ratio of
phosphorylated tau to total tau, student’s t-test was used to determine
statistical differences. For LC-MS/MS SWATH data, multiple t-tests were
used to determine statistical differences. Statistical significance was
determined at p < 0.05. Significance for all tests was defined as follows:
p ≤ 0.05 (*), p < 0.01 (**), p < 0.001 (***).
3. Results & discussion
Increasing evidence has shown that thrombin, and thrombin-related
proteins are elevated in the brains of AD patients [11]. Furthermore,
studies using amyloid-based AD transgenic mice models have implicated
thrombin as a protein of interest [8,19]. Although thrombin accumula
tion is co-localized with tau aggregation [20], thrombin’s potential role
in tau-based animal models has not been explored. In the current pilot
study, we examined how inhibiting thrombin may alter tau-related
pathologic processes.
Oxidative stress resulting from generation of high levels of ROS in AD
is associated with neuron injury, Aβ accumulation, and tau phosphory
lation [21,22]. A meditator of several physiologic functions, NO is a
pathological mediator in the brain when continuously produced [22],
and increased NO and inducible nitric oxide synthase (iNOS) iNOS have
been documented in AD models [23,24]. Another source of noxious ROS
in the brain is NADPH oxidase (NOX), a family of enzymes that directly
regulate ROS production [25]. There is growing evidence that the iso
forms NOX1, NOX2, and NOX4 are upregulated in a variety of neuro
degenerative disease. Here, we evaluate the expression of both iNOS and
NOX4 by western blot (Fig. 1A). The expression of iNOS was signifi
cantly different across groups (F = 8.175, p < 0.01). iNOS expression

Fig. 1. Dabigatran reduces expression of oxidative stress-related proteins in Tg4510 mouse brains. Brain homogenates from wild type mice, Tg4510 mice (TgVehicle), and Tg4510 mice treated with dabigatran (Tg-Dabigatran) were analyzed by western blot (A) for iNOS (B) and NOX4 (C). Mean ± SEM (n = 4), significance
determined by one-way ANOVA with post-hoc Bonferroni, **p ≤ 0.01 vs. Wild Type, #p < 0.05 vs. Tg-Vehicle, ##p < 0.01 vs. Tg-Vehicle.
3
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Fig. 2. Dabigatran diminishes levels of phosphorylated tau species in Tg4510 mice. Brain homogenates from wild type mice, Tg4510 mice (Tg-Vehicle), and
Tg4510 mice treated with dabigatran (Tg-Dabigatran) were analyzed by western blot for total tau (A) tau S396 (B) and tau S416 (C). Mean ± SEM (WT n = 5, TgVehicle n = 6, Tg-Dabigatran n = 4), significance determined one-way ANOVA with post-hoc Bonferroni, ***p < 0.001 vs. Wild Type, #p ≤ 0.05 vs. Tg-Vehicle.

related to inflammation (COX2, GFAP, and ICAM5) (Fig. 4C).
Dabigatran treatment significantly increased the levels of a number
of cell signaling-related proteins (Fig. 4B). Literature implicates
dysfunctional MAPK in neurodegenerative diseases, especially AD. Here,
the MAPK-related proteins MP2K1 and MP2K2 were reduced in Tg4510
compared to wild type, and significantly elevated in the brains of
dabigatran treated Tg4510 mice compared to vehicle. MP2K1 and
MP2K2 are responsible for the activation of the ERK signaling pathway,
thought to regulate mechanisms of cell growth, differentiation, and
survival [29]. Dabigatran treatment also increased expression of MK08
(JNK1), which is involved in both neuronal degeneration and regener
ation, as well as autophagy [30]. Additionally, dabigatran treatment
increased expression of dynamin-1 (DYN1), a protein shown to be
essential for synaptic vesicle recycling and, hence, for memory forma
tion and information processing [31]. The relationship of both MK08
and DYN1 to autophagy and organelle recycling suggests these path
ways should be further explored in light of the literature showing that
autophagosome-lysosomal degradation is impaired and AD [32].

Table 1
Ratio of phosphorylated tau to total tau is decreased in Tg4510 mice
treated with dabigatran. Brain homogenates from Tg4510 mice (Tg-Vehicle),
and Tg4510 mice treated with dabigatran (Tg-Dabigatran) were analyzed by
western blot for total tau, tau S396, and tau S416. The ratio of phosphorylated
tau to total tau was calculated for S396 and S416. Values presented as Mean ±
SEM. Significance was determined by student’s t-test, *p ≤ 0.05.
Tau phosphorylation
site

Tg-Vehicle

Tg-Dabigatran

p value
(significance)

S396

1.010 ±
.2061
1.005 ±
.2938

0.6425 ±
.2423
0.6656 ±
.2358

0.0163 (*)

S416

0.0103 (*)

treatment in the Tg4510 mice, visualized with a volcano plot (Fig. 3B).
Significant differences were detected in coagulation proteins (ANT3,
FIBB, ITB2, and THRB) (Fig. 4A), cell signaling-related proteins (DYN1,
KPCB, MK08, MP2K1, MP2K2, and RACK1) (Fig. 4B), and proteins
4
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Table 2
List of proteins and corresponding abbreviations. Proteins of interest were
identified, classified, and categorized based on previous literature. Proteins were
obtained from UniProt and data obtained by LC-MS/MS with SWATH acquisi
tion were analyzed in Skyline.
Pathway

Abbreviation

Full Protein Name

Alzheimer’s
Disease

A4
ACTN2
ANS1B

Amyloid-beta A4 protein (APP)
Alpha-actinin-2
Ankyrin repeat and sterile alpha motif
domain-containing protein 1B (Amyloid-beta
protein intracellular domain-associated
protein 1)
Apolipoprotein E (Apo-E)
Beta-secretase 1
Beta-secretase 2
Ras GTPase-activating protein-binding
protein 2
Glucose-6-phosphate 1-dehydrogenase X
Guanine nucleotide-binding protein G(z)
subunit alpha
Neuron-specific calcium-binding protein
hippocalcin
Calcium/calmodulin-dependent protein
kinase type II subunit alpha
Sodium/calcium exchanger 2
Nck-associated protein 1
Protein kinase C and casein kinase substrate in
neurons protein 1 (Syndapin-1)
Protocadherin 1
Synaptic vesicle glycoprotein 2B
Ras/Rap GTPase-activating protein SynGAP
Microtubule-associated protein tau

APOE
BACE1
BACE2
G3BP2
G6PD1
GNAZ
HPCA
KCC2A
NAC2
NCKP1
PACN1

Cellular
Signaling

Q8CFX3
SV2B
SYGP1
TAU
(Human)
TAU (Mouse)
TAU (Total)
TBB3
TLN1
TTBK2
VIME
CDK5
DYN1
MK01
MK03
MK08
MK09
MP2K1
MP2K2

Coagulation
Cascade

KPCA
KPCB
KPCD
RACK1
ROCK1
ROCK2
ANT3
FA5
FA8

Inflammation
Related

FA10
FIBA
FIBB
ITAL
ITAM
ITAV
ITB2
ITB3
THRB
COX2
DLG4
GFAP
ICAM1
ICAM5
MILK2
NFKB1
NOS3

Table 2 (continued )
Pathway

Abbreviation

Full Protein Name

PARK7
PTPRC
TLR4
VCAM1

Protein/nucleic acid deglycase DJ-1
Receptor-type tyrosine-protein phosphatase C
Toll-like receptor 4
Vascular cell adhesion protein 1

Finally, dabigatran treatment increased the level of PKC-β (KPCB),
which has been implicated as a critical enzyme in learning and memory
function [33]. Elevation of PKC-β is consistent with the increase in
DYN1, suggesting that future, long-term studies probing the cognitive
effects of dabigatran in this AD model are warranted.
To examine AD-related pathology, we performed LC-MS/MS SWATH
analysis on a variety of AD-related proteins. A number of classically
studied AD-related proteins demonstrated significant differences be
tween wild type and Tg4510 mice, including ApoE, BACE1, TAU
(Human), TAU (Mouse), and TAU (total) (Fig. 5A). To further explore
AD-related pathology, we performed LC-MS/MS SWATH analysis on a
variety of proteins previously found to be altered in sporadic AD and tau
pathology, identified through literature review [34]. Here, G6PD1,
HPCA, KCC2A, and VIME were found to be significantly different in
Tg4510 mice as compared to wild type (Fig. 5B). Dabigatran treatment
increased the levels of HPCA and KCC2A to roughly those found in wild
type mice. Furthermore, ANS1B, NCKP1, SV2B, and SYGP were signif
icantly increased with dabigatran treatment (Fig. 5B). In a previous
report analyzing tau pathology in human AD brains, these proteins were
found to be significantly downregulated in late-stage AD [34]. ANS1B
(Ankyrin repeat and sterile alpha motif domain-containing protein 1B) is
a scaffold protein localized to the post-synaptic density with an identi
fied role in facilitating long-term potentiation (LTP). Additionally,
ANS1B has been found to regulate endothelial barrier function and
permeability [35]. SV2B (synaptic vesicle glycoprotein 2B) is a mediator
of synaptic vesicle transport and exocytosis, and an increase in SV2B
expression has previously been tied to behavioral improvements in mice
following environmental enrichment [36]. SYGP1 (Ras/RTP GTPase
activating protein) regulates the trafficking of α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors to the
cell membrane, and therefore plays a critical role in regulating neuronal
plasticity, synaptic function, and cognition [37,38]. Together, these
findings suggest that dabigatran treatment may increase neuronal
function at the synapse and promote improved plasticity and learning
potential.
When viewing these results, it is important to recognize that dabi
gatran may exert beneficial effects by mechanisms other than direct
inhibition of thrombin-receptor-mediated pathways. Thrombin activity
drives the formation of fibrin, and fibrin has been identified as a po
tential pathological mediator in AD [39]. Anti-coagulant proteins, such
as activated protein C (APC), act in opposition to thrombin [40] and
promote anti-inflammatory processes through differential activation of
the same receptor [41,42]. This may, in part, help to explain the acti
vation of protective MAPK signaling processes following dabigatran
treatment. This is supported by the finding that dabigatran treatment
significantly increased ANT3 (antithrombin III), a natural thrombin in
hibitor (Fig. 4A).
These findings represent preliminary data from a short-term pilot
study, as such must be interpreted with a degree of caution. While the
expression of both iNOS and NOX4 were significantly decreased with
dabigatran treatment, further analysis of enzymatic activity may be
required to better understand the anti-oxidant effect of dabigatran.
Furthermore, in some cases, as in NOX4, dabigatran significantly alters
the impact of a marker that is not significantly changed from wild type to
Tg4510 mouse. Without dabigatran treatment in the wild type animals,
we cannot definitively state whether the positive effects of dabigatran
treatment displayed are specific to the Tg4510 model. Future investi
gation of the therapeutic benefits of dabigatran treatment should

Microtubule-associated protein tau
Microtubule-associated protein tau
Tubulin beta-3 chain
Talin-1
Tau-tubulin kinase 2
Vimentin
Cyclin-dependent-like kinase 5
Dynamin-1
Mitogen-activated protein kinase 1
Mitogen-activated protein kinase 3
Mitogen-activated protein kinase 8
Mitogen-activated protein kinase 9
Dual specificity mitogen-activated protein
kinase kinase 1
Dual specificity mitogen-activated protein
kinase kinase 2
Protein kinase C alpha type
Protein kinase C beta type
Protein kinase C delta type
Receptor of activated protein C kinase 1
Rho-associated protein kinase 1
Rho-associated protein kinase 2
Antithrombin-III
Coagulation factor V (Activated protein C
cofactor)
Coagulation factor VIII (Procoagulant
component)
Coagulation factor X
Fibrinogen alpha chain
Fibrinogen beta chain
Integrin alpha-L
Integrin alpha-M
Integrin alpha-V
Integrin beta-2
Integrin beta-3
Thrombin
Cytochrome c oxidase subunit 2
Disks large homolog 4
Glial fibrillary acidic protein (GFAP)
Intercellular adhesion molecule 1
Intercellular adhesion molecule 5
MICAL-like protein 2
Nuclear factor NF-kappa-B p105 subunit
Nitric oxide synthase, endothelial
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Fig. 3. Proteomic expression differences between wild type mice, Tg-Vehicle, and Tg-Dabigatran mice are detected by LC-MS/MS SWATH analysis. (A)
Volcano plot of data sets from brain homogenates of wild type mice and Tg4510 mice (Tg-Vehicle). (B) Volcano plot of data sets from brain homogenates of Tg4510
mice (Tg-Vehicle) and Tg4510 mice treated with dabigatran (Tg-Dabigatran).
Fig. 4. Treatment of Tg4510 mice with dabigatran
causes widespread differences in protein expres
sion. Proteomic expression differences between wild
type mice, Tg4510 mice (Tg-Vehicle), and Tg4510
mice treated with dabigatran (Tg-Dabigatran) are
detected by LC-MS/MS SWATH analysis. Functional
categories of proteins that show significant expression
differences are shown as follows: (A) coagulation
cascade, (B) cell signaling, and (C) inflammationrelated. Mean ± SEM (n = 5), statistical differences
determined by multiple t-tests, *p ≤ 0.05 vs. Wild
Type, #p ≤ 0.05 vs. Tg-Vehicle.
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Fig. 5. Treatment of Tg4510 mice with dabigatran
alters expression of proteins related to Alz
heimer’s disease pathology. Proteomic expression
differences between wild type mice, Tg4510 mice
(Tg-Vehicle), and Tg4510 mice treated with dabiga
tran (Tg-Dabigatran) are detected by LC-MS/MS
SWATH analysis. (A) classic AD-associated proteins
and (B) proteins determined by literature search to be
altered in sporadic AD or tau pathology that show
significant expression differences are shown. Mean ±
SEM (n = 5), statistical differences determined by
multiple t-tests, *p ≤ 0.05 vs. Wild Type, #p ≤ 0.05
vs. Tg-Vehicle.

include these relevant control groups, in order to better understand the
context in which dabigatran exerts its effects.
Studies in both animal models and human populations utilizing
anticoagulant therapies support the notion that mediators of the coag
ulation cascade may promote AD pathology. A recent study showed that
treatment of TgCRND8 transgenic AD mice with dabigatran improved
spatial memory deficits and reduced neuroinflammation and amyloid
plaque formation [19]. In that study, animals were two months-of-age at
the start of the study and received drug treatment for one year. In the
current study, we explored the possible acute effects of dabigatran on an
older population with established disease. Our results suggest that even
a short intervention in older animals produces benefits, as demonstrated
by the reduction in oxidative stress and AD markers we document.
Future studies are needed to further define the beneficial effects of
dabigatran over an extended time course and in additional transgenic
models of AD. Our pilot study in a tau-based mouse model adds
important information to a growing body of data implicating thrombin

inhibition as a therapeutic strategy in AD. An open-label study of a
hirudin (natural antithrombin anticoagulant) compound in 84 patients
with mild-to-moderate AD found that hirudin plus donepezil reduced
the rate of cognitive decline compared to donepezil alone, suggesting
that direct thrombin inhibition may indeed be an effective strategy for
treating this neurodegenerative disease [43]. In a longitudinal,
community-based study, use of dabigatran was associated with a lower
risk of new-onset dementia compared to warfarin [44]. Along with our
data, these studies demonstrate that targeting thrombin could be
beneficial in AD and that thrombin inhibitors could play a role in a drug
treatment regimen for AD.
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